Loading...

Craneware

AIM:CRW
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRW
AIM
£500M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The last earnings update was 135 days ago. More info.


Add to Portfolio Compare Print
  • Craneware has significant price volatility in the past 3 months.
CRW Share Price and Events
7 Day Returns
8.5%
AIM:CRW
3.8%
GB Healthcare Services
0.3%
GB Market
1 Year Returns
-17.7%
AIM:CRW
5.6%
GB Healthcare Services
-1.9%
GB Market
CRW Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Craneware (CRW) 8.5% -37.7% -26.8% -17.7% 101.6% 260.2%
GB Healthcare Services 3.8% -13.8% -7.7% 5.6% 42% 108.9%
GB Market 0.3% 1.9% 0.4% -1.9% 11.4% 6.7%
1 Year Return vs Industry and Market
  • CRW underperformed the Healthcare Services industry which returned 5.6% over the past year.
  • CRW underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -1.9% over the past year.
Price Volatility
CRW
Industry
5yr Volatility vs Market

CRW Value

 Is Craneware undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Craneware to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Craneware.

AIM:CRW Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:CRW
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6.7%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.08
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.081 (1 + (1- 19%) (0%))
1.054
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (1.054 * 6.65%)
8.24%

Discounted Cash Flow Calculation for AIM:CRW using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Craneware is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

AIM:CRW DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.24%)
2020 12.63 Analyst x3 11.67
2021 15.60 Analyst x3 13.32
2022 16.95 Est @ 8.63% 13.36
2023 18.03 Est @ 6.41% 13.14
2024 18.91 Est @ 4.85% 12.73
2025 19.62 Est @ 3.76% 12.20
2026 20.21 Est @ 3% 11.61
2027 20.71 Est @ 2.47% 10.99
2028 21.14 Est @ 2.1% 10.37
2029 21.53 Est @ 1.84% 9.75
Present value of next 10 years cash flows $119.14
AIM:CRW DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $21.53 × (1 + 1.23%) ÷ (8.24% – 1.23%)
$310.82
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $310.82 ÷ (1 + 8.24%)10
$140.83
AIM:CRW Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $119.14 + $140.83
$259.96
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $259.96 / 26.33
$9.87
AIM:CRW Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of AIM:CRW)
0.801
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $9.87 x 0.801
£7.91
Value per share (GBP) From above. £7.91
Current discount Discount to share price of £19.00
= -1 x (£19.00 - £7.91) / £7.91
-140.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Craneware is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Craneware's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Craneware's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:CRW PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.63
AIM:CRW Share Price ** AIM (2019-07-18) in GBP £19
AIM:CRW Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.249 $23.73
Europe Healthcare Services Industry PE Ratio Median Figure of 20 Publicly-Listed Healthcare Services Companies 22.98x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 791 Publicly-Listed Companies 16.52x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Craneware.

AIM:CRW PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:CRW Share Price ÷ EPS (both in USD)

= 23.73 ÷ 0.63

37.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Craneware is overvalued based on earnings compared to the Europe Healthcare Services industry average.
  • Craneware is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Craneware's expected growth come at a high price?
Raw Data
AIM:CRW PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 37.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
4.3%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 1.84x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 572 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

AIM:CRW PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 37.57x ÷ 4.3%

8.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Craneware is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Craneware's assets?
Raw Data
AIM:CRW PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.14
AIM:CRW Share Price * AIM (2019-07-18) in GBP £19
AIM:CRW Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.249 $23.73
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 3.12x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,377 Publicly-Listed Companies 1.51x
AIM:CRW PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:CRW Share Price ÷ Book Value per Share (both in USD)

= 23.73 ÷ 2.14

11.11x

* Primary Listing of Craneware.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Craneware is overvalued based on assets compared to the GB Healthcare Services industry average.
X
Value checks
We assess Craneware's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Craneware has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CRW Future Performance

 How is Craneware expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Craneware expected to grow at an attractive rate?
  • Craneware's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • Craneware's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Craneware's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:CRW Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:CRW Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 4.3%
AIM:CRW Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 8.6%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 14.2%
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 9.6%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:CRW Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:CRW Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 93 1
2021-06-30 86 29 18 5
2020-06-30 78 26 16 5
2019-06-30 71 22 15 4
AIM:CRW Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 72 20 17
2018-09-30 69 25 16
2018-06-30 67 30 16
2018-03-31 65 25 15
2017-12-31 62 19 15
2017-09-30 60 19 14
2017-06-30 58 18 14
2017-03-31 56 15 13
2016-12-31 54 12 12
2016-09-30 52 14 11
2016-06-30 50 15 11
2016-03-31 48 16 10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Craneware's earnings are expected to grow by 4.3% yearly, however this is not considered high growth (20% yearly).
  • Craneware's revenue is expected to grow by 8.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:CRW Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Craneware Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:CRW Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30
2021-06-30 0.65 0.70 0.59 2.00
2020-06-30 0.59 0.60 0.57 2.00
2019-06-30 0.53 0.57 0.50 2.00
AIM:CRW Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.63
2018-09-30 0.61
2018-06-30 0.59
2018-03-31 0.57
2017-12-31 0.54
2017-09-30 0.52
2017-06-30 0.50
2017-03-31 0.47
2016-12-31 0.43
2016-09-30 0.41
2016-06-30 0.39
2016-03-31 0.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Craneware is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Craneware's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Craneware has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CRW Past Performance

  How has Craneware performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Craneware's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Craneware's year on year earnings growth rate has been positive over the past 5 years.
  • Craneware's 1-year earnings growth exceeds its 5-year average (15.5% vs 15.2%)
  • Craneware's earnings growth has not exceeded the Europe Healthcare Services industry average in the past year (15.5% vs 21.9%).
Earnings and Revenue History
Craneware's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Craneware Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:CRW Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 71.78 16.83 32.97 13.17
2018-09-30 69.42 16.31 31.30 13.17
2018-06-30 67.07 15.80 29.64 13.17
2018-03-31 64.61 15.19 30.22 11.14
2017-12-31 62.14 14.58 30.81 9.11
2017-09-30 59.97 14.05 29.16 9.11
2017-06-30 57.80 13.53 27.51 9.11
2017-03-31 55.66 12.55 26.54 8.39
2016-12-31 53.52 11.58 25.56 7.67
2016-09-30 51.68 11.08 24.54 7.67
2016-06-30 49.85 10.58 23.51 7.67
2016-03-31 48.10 10.30 22.77 7.33
2015-12-31 46.36 10.02 22.04 6.99
2015-09-30 45.59 9.70 21.70 6.99
2015-06-30 44.82 9.39 21.36 6.99
2015-03-31 43.91 9.21 20.97 6.98
2014-12-31 43.00 9.03 20.58 6.98
2014-09-30 42.79 8.82 20.66 6.98
2014-06-30 42.57 8.61 20.74 6.98
2014-03-31 42.52 8.60 20.63 6.96
2013-12-31 42.47 8.60 20.52 6.93
2013-09-30 41.96 8.45 20.34 6.93
2013-06-30 41.45 8.30 20.17 6.93
2013-03-31 41.95 8.87 20.80 6.89
2012-12-31 42.44 9.43 21.43 6.84
2012-09-30 41.76 9.16 21.17 6.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Craneware has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Craneware used its assets more efficiently than the Europe Healthcare Services industry average last year based on Return on Assets.
  • Craneware has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Craneware's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Craneware has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CRW Health

 How is Craneware's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Craneware's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Craneware is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Craneware has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Craneware's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Craneware has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Craneware Company Filings, last reported 6 months ago.

AIM:CRW Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 56.26 0.00 38.67
2018-09-30 56.26 0.00 38.67
2018-06-30 51.65 0.00 52.83
2018-03-31 51.65 0.00 52.83
2017-12-31 63.23 0.00 52.21
2017-09-30 63.23 0.00 52.21
2017-06-30 59.36 0.00 53.17
2017-03-31 59.36 0.00 53.17
2016-12-31 52.37 0.00 45.10
2016-09-30 52.37 0.00 45.10
2016-06-30 52.81 0.00 48.81
2016-03-31 52.81 0.00 48.81
2015-12-31 49.29 0.00 44.98
2015-09-30 49.29 0.00 44.98
2015-06-30 47.63 0.00 41.83
2015-03-31 47.63 0.00 41.83
2014-12-31 44.45 0.00 36.37
2014-09-30 44.45 0.00 36.37
2014-06-30 44.92 0.00 32.61
2014-03-31 44.92 0.00 32.61
2013-12-31 42.21 0.00 30.63
2013-09-30 42.21 0.00 30.63
2013-06-30 41.32 0.00 30.28
2013-03-31 41.32 0.00 30.28
2012-12-31 38.38 0.00 28.62
2012-09-30 38.38 0.00 28.62
  • Craneware has no debt.
  • Craneware has not taken on any debt in the past 5 years.
  • Craneware has no debt, it does not need to be covered by operating cash flow.
  • Craneware has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Craneware's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Craneware has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CRW Dividends

 What is Craneware's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.35%
Current annual income from Craneware dividends. Estimated to be 1.89% next year.
If you bought £2,000 of Craneware shares you are expected to receive £27 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Craneware's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (1.94%).
  • Craneware's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.46%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:CRW Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.5%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.2%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 1.9%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:CRW Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 0.51 1.00
2021-06-30 0.47 5.00
2020-06-30 0.42 5.00
2019-06-30 0.38 5.00
AIM:CRW Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2018-10-12 0.320 0.949
2018-09-04 0.320 0.763
2017-10-12 0.254 1.116
2017-09-05 0.260 1.519
2016-10-20 0.228 1.458
2016-09-06 0.228 1.436
2015-10-22 0.219 1.896
2015-09-08 0.219 2.095
2014-10-17 0.214 2.486
2014-09-16 0.214 2.577
2013-09-10 0.174 2.052
2013-09-09 0.174 2.759
2013-03-01 0.174 2.861
2012-09-05 0.158 2.511
2012-09-04 0.164 2.744
2012-09-03 0.164 3.017
2011-08-31 0.141 2.319
2011-08-30 0.141 1.830
2010-09-06 0.120 1.337
2010-09-03 0.120 1.972
2010-02-22 0.135 2.377
2009-09-07 0.095 1.759
2009-06-30 0.095 2.489
2009-03-26 0.511 15.641
2009-02-23 0.053 1.693
2008-09-09 0.043 1.431

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Craneware's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.9x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.6x coverage).
X
Income/ dividend checks
We assess Craneware's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Craneware afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Craneware has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CRW Management

 What is the CEO of Craneware's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Keith Neilson
COMPENSATION $878,000
AGE 50
TENURE AS CEO 20.5 years
CEO Bio

Mr. Keith Neilson co-founded Craneware PLC in 1999 and has served as its Chief Executive Officer ever since. Keith’s direction has helped Craneware to win multiple prestigious awards in such areas as international achievement, business growth strategy and innovation. Keith was named The Entrepreneurial Exchange’s “Emerging Entrepreneur of the Year 2003” and was a finalist in the 2004 World Young Business Achiever Award, winning the Award of Excellence in the Business Strategy category. He received the UK Software & Technology Entrepreneur of the Year Award from Ernst & Young in 2008 and was the Insider Elite Young Business Leader of the Year in 2009. Prior to launching Craneware, he worked primarily in international management, where he handled sales, marketing and technical consulting for companies with operations around the world. He is a Director at Craneware. He studied Physics at Heriot-Watt University, Edinburgh, receiving a bachelor’s degree in 1991. He is an active member of the Young President Organisation (YPO), a syndicate member and Partner in Par Equity LLP, a board member of Code Clan, the Scottish Digital Skills Academy and the Scottish North American Business Council (SNABC). He is also proud to be a Patron of the Princes Trust and a Trustee of the Polar Academy both charitable organisations that work for the benefit of young people.

CEO Compensation
  • Keith's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Keith's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure of the Craneware management team in years:

10.8
Average Tenure
  • The average tenure for the Craneware management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Keith Neilson

TITLE
Co-Founder
COMPENSATION
$878K
AGE
50
TENURE
20.5 yrs

Craig Preston

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
$656K
AGE
48
TENURE
10.8 yrs

Marty Smith

TITLE
Chief Technology Officer

Derek Paterson

TITLE
Chief Information Officer
TENURE
18.8 yrs

Seth Droe

TITLE
Executive Vice President of Sales
TENURE
6.2 yrs

Mark Montgomery

TITLE
Chief Marketing Officer
TENURE
5.8 yrs

Issy Urquhart

TITLE
Chief People Officer
TENURE
3.6 yrs

Karen Bowden

TITLE
Executive Vice President of Customer Management
TENURE
18.5 yrs
Board of Directors Tenure

Average tenure and age of the Craneware board of directors in years:

8.3
Average Tenure
62.5
Average Age
  • The tenure for the Craneware board of directors is about average.
Board of Directors

George Elliott

TITLE
Non-Executive Chairman
COMPENSATION
$104K
AGE
66
TENURE
11.9 yrs

Keith Neilson

TITLE
Co-Founder
COMPENSATION
$878K
AGE
50

Craig Preston

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
$656K
AGE
48
TENURE
10.8 yrs

Ron Verni

TITLE
Senior Independent Non-Executive Director
COMPENSATION
$59K
AGE
71

Colleen Blye

TITLE
Non-Executive Director
COMPENSATION
$56K
AGE
59
TENURE
5.7 yrs

Russ Rudish

TITLE
Non-Executive Director
COMPENSATION
$52K
AGE
66
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
10. Sep 18 Buy Keith Neilson Individual 07. Sep 18 07. Sep 18 4,848 £30.85 £149,411
X
Management checks
We assess Craneware's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Craneware has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CRW News

Simply Wall St News

Does Craneware (LON:CRW) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. … One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. … You can take a look at the company's revenue and earnings growth trend, in the chart below.

Simply Wall St -

A Holistic Look At Craneware plc (LON:CRW)

Attractive stocks have exceptional fundamentals. … In the case of Craneware plc (LON:CRW), there's … track record

Simply Wall St -

Craneware plc (LON:CRW): Can Growth Justify Its April Share Price?

Craneware plc (LON:CRW) is considered a high growth stock. … However its last closing price of £24 left investors wondering whether this growth has already been factored into the share price. … Craneware is poised for extremely high earnings growth in the near future

Simply Wall St -

Have Insiders Been Buying Craneware plc (LON:CRW) Shares This Year?

So shareholders might well want to know whether insiders have been buying or selling shares in Craneware plc (LON:CRW). … Craneware Insider Transactions Over The Last Year. … That means that an insider was happy to buy shares at above the current price.

Simply Wall St -

How Does Craneware plc's (LON:CRW) Earnings Growth Stack Up Against Industry Performance?

After reading Craneware plc's (LON:CRW) latest earnings update (31 December 2018), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … CRW's trailing twelve-month earnings (from 31 December 2018) of US$17m has. … Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of 15%, indicating the rate at which CRW is growing has accelerated

Simply Wall St -

Is Craneware plc (LON:CRW) Overpaying Its CEO?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Keith Neilson's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Craneware plc has a market cap of UK£709m, and is paying total annual CEO compensation of US$878k.

Simply Wall St -

Did You Miss Craneware's Whopping 356% Share Price Gain?

One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price. … Over half a decade, Craneware managed to grow its earnings per share at 14% a year. … This EPS growth is slower than the share price growth of 35% per year, over the same period.

Simply Wall St -

How Craneware plc (LON:CRW) Can Impact Your Portfolio Volatility

If you're interested in Craneware plc (LON:CRW), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … To use beta as an investor, you must first understand that the overall market has a beta of one.

Simply Wall St -

Craneware plc (LON:CRW) Is Employing Capital Very Effectively

To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … What is Return On Capital Employed (ROCE)? … How Do You Calculate Return On Capital Employed

Simply Wall St -

Will Craneware plc's (LON:CRW) Earnings Grow In The Next 12 Months?

Since Craneware plc (LON:CRW) released its earnings in June 2018,. … in-line with historical trends, with earnings growth rate expected to be 13% in the upcoming year, relative to the past five-year average earnings growth of 14% per year … Presently, with latest-twelve-month earnings at US$16m, we should see this growing to US$18m by 2020.

Simply Wall St -

CRW Company Info

Description

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company offers patient engagement solutions, such as InSight Medical Necessity, a software-as-a-service (SaaS) solution that provides medical necessity validation for United States payers and advance beneficiary notice creation; and Trisus Patient Payment, which provides hospitals and health systems to modernize patient payment. It also provides charge capture and pricing solutions, such as Chargemaster Toolkit, Chargemaster Toolkit Discovery Viewer, and Chargemaster Toolkit Corporate Discovery Viewer for capturing optimal legitimate reimbursement for providers; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Pricing Analyzer, a SaaS solution that simplifies the price modelling process; Reference Plus, a SaaS solution to perform Chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; and supporting modules, including Online Reference Toolkit, interface scripting module, and supplies assistant. In addition, the company provides Trisus Claims Informatics, a software that automates claim and coding reviews; InSight Audit, a Web-based audit management tool for healthcare organizations to manage government and commercial audits; and InSight Denials to analyze, track, trend, and report on denial data. Further, it provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; consulting and professional services; and sales and marketing, product development, and software development services. Craneware plc was founded in 1999 and is headquartered in Edinburgh, the United Kingdom.

Details
Name: Craneware plc
CRW
Exchange: AIM
Founded: 1999
£500,241,272
26,328,488
Website: http://public.craneware.com
Address: Craneware plc
1 Tanfield,
Edinburgh,
EH3 5DA,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM CRW Ordinary Shares London Stock Exchange AIM Market GB GBP 13. Sep 2007
OTCPK CRWR.F Ordinary Shares Pink Sheets LLC US USD 13. Sep 2007
Number of employees
Current staff
Staff numbers
320
Craneware employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 21:12
End of day share price update: 2019/07/18 00:00
Last estimates confirmation: 2019/07/03
Last earnings filing: 2019/03/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.